Structure-based studies of chemokine receptors

Current Opinion in Structural Biology

Volumn 23, Issue 4, 2013, Pages 539-546

  Zhu, Lan ^a   Zhao, Qiang ^a   Wu, Beili ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; G PROTEIN COUPLED RECEPTOR; MU OPIATE RECEPTOR; NOCICEPTIN ORPHANIN FQ PEPTIDE RECEPTOR; OPIATE RECEPTOR; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ALPHA HELIX; BETA HAIRPIN; BINDING SITE; COMPLEX FORMATION; COMPUTER MODEL; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DIMERIZATION; DISULFIDE BOND; EXTRACELLULAR LOOP; HIGH THROUGHPUT SCREENING; HUMAN; LIGAND BINDING; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

BINDING SITES; CELL MOVEMENT; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DIMERIZATION; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIGANDS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, CXCR4;

EID: 84881112796     PISSN: 0959440X     EISSN: 1879033X     Source Type: Journal    
DOI: 10.1016/j.sbi.2013.05.003     Document Type: Review

References (50)

1. Baggiolini M. Chemokines in pathology and medicine. J Intern Med 2001, 250:91-104.
2. Allen S.J., Crown S.E., Handel T.M. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 2007, 25:787-820.
3. Wu B., Chien E.Y., Mol C.D., Fenalti G., Liu W., Katritch V., Abagyan R., Brooun A., Wells P., Bi F.C., et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010, 330:1066-1071.
4. Maggio R., Vogel Z., Wess J. Coexpression studies with mutant muscarinic/adrenergic receptors provide evidence for intermolecular 'cross-talk' between G-protein-linked receptors. Proc Natl Acad Sci U S A 1993, 90:3103-3107.
5. Kniazeff J., Saintot P.P., Goudet C., Liu J., Charnet A., Guillon G., Pin J.P. Locking the dimeric GABA(B) G-protein-coupled receptor in its active state. J Neurosci 2004, 24:370-377.
6. Han Y., Moreira I.S., Urizar E., Weinstein H., Javitch J.A. Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat Chem Biol 2009, 5:688-695.
7. Blois T.M., Bowie J.U. G-protein-coupled receptor structures were not built in a day. Protein Sci 2009, 18:1335-1342.
8. Topiol S., Sabio M. X-ray structure breakthroughs in the GPCR transmembrane region. Biochem Pharmacol 2009, 78:11-20.
9. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., Le Trong I., Teller D.C., Okada T., Stenkamp R.E., et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000, 289:739-745.
10. Cherezov V., Rosenbaum D.M., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., Choi H.J., Kuhn P., Weis W.I., Kobilka B.K., et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318:1258-1265.
11. Jaakola V.P., Griffith M.T., Hanson M.A., Cherezov V., Chien E.Y., Lane J.R., Ijzerman A.P., Stevens RC The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008, 322:1211-1217.
12. Chien E.Y., Liu W., Zhao Q., Katritch V., Han G.W., Hanson M.A., Shi L., Newman A.H., Javitch J.A., Cherezov V., et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 2010, 330:1091-1095.
13. Shimamura T., Shiroishi M., Weyand S., Tsujimoto H., Winter G., Katritch V., Abagyan R., Cherezov V., Liu W., Han G.W., et al. Structure of the human histamine H1 receptor complex with doxepin. Nature 2011, 475:65-70.
14. Hanson M.A., Roth C.B., Jo E., Griffith M.T., Scott F.L., Reinhart G., Desale H., Clemons B., Cahalan S.M., Schuerer S.C., et al. Crystal structure of a lipid G protein-coupled receptor. Science 2012, 335:851-855.
15. Haga K., Kruse A.C., Asada H., Yurugi-Kobayashi T., Shiroishi M., Zhang C., Weis W.I., Okada T., Kobilka B.K., Haga T., et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 2012, 482:547-551.
16. Zhang C., Srinivasan Y., Arlow D.H., Fung J.J., Palmer D., Zheng Y., Green H.F., Pandey A., Dror R.O., Shaw D.E., et al. High-resolution crystal structure of human protease-activated receptor 1. Nature 2012, 492:387-392.
17. Wu H., Wacker D., Mileni M., Katritch V., Han G.W., Vardy E., Liu W., Thompson A.A., Huang X.P., Carroll F.I., et al. Structure of the human κ-opioid receptor in complex with JDTic. Nature 2012, 485:327-332.
18. White J.F., Noinaj N., Shibata Y., Love J., Kloss B., Xu F., Gvozdenovic-Jeremic J., Shah P., Shiloach J., Tate C.G., et al. Structure of the agonist-bound neurotensin receptor. Nature 2012, 490:508-513.
19. Kufareva I., Rueda M., Katritch V., Stevens R.C., Abagyan R., GPCR Dock 2010 participants Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment. Structure 2011, 19:1108-1126.
20. Levoye A., Balabanian K., Baleux F., Bachelerie F., Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009, 113:6085-6093.
21. Sohy D., Yano H., de Nadai P., Urizar E., Guillabert A., Javitch J.A., Parmentier M., Springael J.Y. Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of 'selective' antagonists. J Biol Chem 2009, 284:31270-31279.
22. Salanga C.L., O'Hayre M., Handel T. Modulation of chemokine receptor activity through dimerization and crosstalk. Cell Mol Life Sci 2009, 66:1370-1386.
23. Carter P.H., Tebben A.J. The use of receptor homology modeling to facilitate the design of selective chemokine receptor antagonists. Methods Enzymol 2009, 461:249-279. (Chapter 12).
24. Kimura S.R., Tebben A.J., Langley D.R. Expanding GPCR homology model binding sites via a balloon potential: a molecular dynamics refinement approach. Proteins 2008, 71:1919-1929.
25. Sherman W., Beard H.S., Farid R. Use of an induced fit receptor structure in virtual screening. Chem Biol Drug Des 2006, 67:83-84.
26. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., Shiraishi M., Aramaki Y., Okonogi K., Ogawa Y., et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 1999, 96:5698-5703.
27. Moree W.J., Kataoka K., Ramirez-Weinhouse M.M., Shiota T., Imai M., Tsutsumi T., Sudo M., Endo N., Muroga Y., Hada T., et al. Potent antagonists of the CCR2b receptor. Part 3: SAR of the (R)-3-aminopyrrolidine series. Bioorg Med Chem Lett 2008, 18:1869-1873.
28. Berkhout T.A., Blaney F.E., Bridges A.M., Cooper D.G., Forbes I.T., Gribble A.D., Groot P.H., Hardy A., Ife R.J., Kaur R., et al. CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach. J Med Chem 2003, 46:4070-4086.
29. Garcia-Perez J., Rueda P., Alcami J., Rognan D., Arenzana-Seisdedos F., Lagane B., Kellenberger E. Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5). J Biol Chem 2011, 286:33409-33421.
30. Shahlaei M., Madadkar-Sobhani A., Fassihi A., Saghaie L. Exploring a model of a chemokine receptor/ligand complex in an explicit membrane environment by molecular dynamics simulation: the human CCR1 receptor. J Chem Inform Model 2011, 51:2717-2730.
31. Huang D., Gu Q., Ge H., Ye J., Salam N.K., Hagler A., Chen H., Xu J. On the value of homology models for virtual screening: discovering hCXCR3 antagonists by pharmacophore-based and structure-based approaches. J Chem Inf Model 2012, 52:1356-1366.
32. Gadhe C.G., Kothandan G., Cho S.J. Computational modeling of human coreceptor CCR5 antagonist as a HIV-1 entry inhibitor: using an integrated homology modeling, docking, and membrane molecular dynamics simulation analysis approach. J Biomol Struct Dyn 2012, 10.1080/07391102.2012.732342.
33. Gadhe C.G., Kothandan G., Cho S.J. Binding site exploration of CCR5 using in silico methodologies: a 3D-QSAR approach. Arch Pharm Res 2013, 36:6-31.
34. Izhak L., Wildbaum G., Zohar Y., Anunu R., Klapper L., Elkeles A., Seagal J., Yefenof E., Ayalon-Soffer M., Karin N. A novel recombinant fusion protein encoding a 20-amino acid residue of the third extracellular (E3) domain of CCR2 neutralizes the biological activity of CCL2. J Immunol 2009, 183:732-739.
35. Zhou H., Tai H.H. Expression and functional characterization of mutant human CXCR4 in insect cells: role of cysteinyl and negatively charged residues in ligand binding. Arch Biochem Biophys 2000, 373:211-217.
36. Wong R.S., Bodart V., Metz M., Labrecque J., Bridger G., Fricker S.P. Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors. Mol Pharmacol 2008, 74:1485-1495.
37. Gupta S.K., Pillarisetti K., Thomas R.A., Aiyar N. Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1alpha: implications for development of selective CXCR4 antagonists. Immunol Lett 2001, 78:29-34.
38. Kofuku Y., Yoshiura C., Ueda T., Terasawa H., Hirai T., Tominaga S., Hirose M., Maeda Y., Takahashi H., Terashima Y., et al. Structural basis of the interaction between chemokine stromal cell-derived factor-1/CXCL12 and its G-protein-coupled receptor CXCR4. J Biol Chem 2009, 284:35240-35250.
39. Manglik A., Kruse A.C., Kobilka T.S., Thian F.S., Mathiesen J.M., Sunahara R.K., Pardo L., Weis W.I., Kobilka B.K., Granier S. Crystal structure of the μ-opioid receptor bound to a morphinan antagonist. Nature 2012, 485:321-326.
40. Granier S., Manglik A., Kruse A.C., Kobilka T.S., Thian F.S., Weis W.I., Kobilka B.K. Structure of the δ-opioid receptor bound to naltrindole. Nature 2012, 485:400-404.
41. Thompson A.A., Liu W., Chun E., Katritch V., Wu H., Vardy E., Huang X.P., Trapella C., Guerrini R., Calo G., et al. Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature 2012, 485:395-399.
42. Johnston J.M., Wang H., Provasi D., Filizola M. Assessing the relative stability of dimer interfaces in g protein-coupled receptors. PLoS Comput Biol 2012, 8:e1002649.
43. Wacker D., Fenalti G., Brown M.A., Katritch V., Abagyan R., Cherezov V., Stevens R.C. Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. J Am Chem Soc 2010, 132:11443-11445.
44. Rasmussen S.G., Choi H.J., Fung J.J., Pardon E., Casarosa P., Chae P.S., Devree B.T., Rosenbaum D.M., Thian F.S., Kobilka T.S., et al. Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. Nature 2011, 469:175-180.
45. Salom D., Lodowski D.T., Stenkamp R.E., Le Trong I., Golczak M., Jastrzebska B., Harris T., Ballesteros J.A., Palczewski K. Crystal structure of a photoactivated deprotonated intermediate of rhodopsin. Proc Natl Acad Sci U S A 2006, 103:16123-16128.
46. Rosenbaum D.M., Zhang C., Lyons J.A., Holl R., Aragao D., Arlow D.H., Rasmussen S.G., Choi H.J., Devree B.T., Sunahara R.K., et al. Structure and function of an irreversible agonist-β(2) adrenoceptor complex. Nature 2011, 469:236-240.
47. Xu F., Wu H., Katritch V., Han G.W., Jacobson K.A., Gao Z.G., Cherezov V., Stevens R.C. Structure of an agonist-bound human A2A adenosine receptor. Science 2011, 332:322-327.
48. Rasmussen S.G., DeVree B.T., Zou Y., Kruse A.C., Chung K.Y., Kobilka T.S., Thian F.S., Chae P.S., Pardon E., Calinski D., et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 2011, 477:549-555.
49. Proudfoot A.E., Power C.A., Rommel C., Wells T.N. Strategies for chemokine antagonists as therapeutics. Semin Immunol 2003, 15:57-65.
50. Handel T.M., Johnson Z., Rodrigues D.H., Dos Santos A.C., Cirillo R., Muzio V., Riva S., Mack M., Déruaz M., Borlat F., et al. An engineered monomer of CCL2 has anti-inflammatory properties emphasizing the importance of oligomerization for chemokine activity in vivo. J Leukoc Biol 2008, 84:1101-1108.